Trial Search Results

Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis

This study is being done to determine if there is a potential benefit of saracatinib in LAM subjects. Based on the information of this trial, additional clinical development trials will be needed. The study will also test the tolerability of 125 mg of saracatinib given once daily over a 9 month period.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Baylor College of Medicine

Collaborator: University of Cincinnati

Stanford Investigator(s):


  • Drug: saracatinib


Phase 2


Inclusion Criteria:

   - Female patients. It should be noted that LAM occurs almost exclusively in women.

   - 18 to 65 years of age.

   - All patients must have a diagnosis of LAM as defined by compatible cystic changes on
   chest computed tomography (CT) and one of the following:

   - Open lung, transbronchial or thoracic needle biopsy consistent with LAM

   - Open or needle abdominal biopsy findings consistent with LAM

   - Clinical findings of tuberous scleroma complex (TSC), renal angiomyolipoma, cystic
   abdominal lymphangiomas, or history of chylous effusion in the chest or abdomen

   - Serum vascular endothelial growth factor D (VEGF-D) > 800 pg/ml

   - Subjects must have had a recent reduction in forced expiratory volume at 1-second
   (FEV1) of > 50ml/year, as shown by at least two pulmonary function testing (PFT)
   measured at least 6 months apart in the last 24 months prior to enrolling study.

Exclusion Criteria:

   - Current infection.

   - Major surgery within the past 2 months

   - Advanced hematologic, renal, hepatic, non-LAM lung disease or metabolic diseases; or
   BMI of >35

   - The use of another investigational drug within 30 days

   - The use of mTOR (mammalian target of rapamycin) inhibitors within 30 days

   - Previous lung transplantation.

   - Inability to attend scheduled clinic visits

   - Inability to give informed consent

   - Inability to perform pulmonary function testing

   - History of malignancy in the past two years, other than squamous or basal cell skin
   cancer or status post successful excision or treatment.

   - Nursing mothers

   - Current or planned pregnancy.

   - Not using adequate contraception (in woman of childbearing potential).

   - Significant clinical change in health in the past 30 days

Ages Eligible for Study

18 Years - 65 Years

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Susan Jacobs, RN MS